EA202090966A1 - МОНОКЛОНАЛЬНЫЕ АНТИ-TrkB АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ - Google Patents

МОНОКЛОНАЛЬНЫЕ АНТИ-TrkB АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Info

Publication number
EA202090966A1
EA202090966A1 EA202090966A EA202090966A EA202090966A1 EA 202090966 A1 EA202090966 A1 EA 202090966A1 EA 202090966 A EA202090966 A EA 202090966A EA 202090966 A EA202090966 A EA 202090966A EA 202090966 A1 EA202090966 A1 EA 202090966A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
methods
trkb
application
diseases
Prior art date
Application number
EA202090966A
Other languages
English (en)
Inventor
Сьюзан Д. Кролл
Мин Гао
Ин ХУ
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA202090966A1 publication Critical patent/EA202090966A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Описаны антитела, которые специфически связываются с TrkB, а также способы их применения. Описаны агонистические антитела, которые являются нейропротекторными, что подтверждается их эффектом в отношении повышения выживаемости ганглионарных клеток сетчатки in vitro, и эти агонистические антитела могут применяться в лечении заболеваний глаз, таких как глаукома. Кроме того, лечение этими агонистическими антителами оказывает положительный эффект в отношении других заболеваний или расстройств нейронов, включая заболевания или расстройства, которые отчасти характеризуются повреждением нейронов. В некоторых вариантах осуществления изобретение включает антитела, которые связываются с TrkB и опосредуют клеточную сигнализацию. Антитела по изобретению могут быть полностью человеческими, не встречающимися в природе антителами, объединенными со вспомогательными веществами в составе лекарственного препарата для инъекций.
EA202090966A 2017-11-30 2018-11-28 МОНОКЛОНАЛЬНЫЕ АНТИ-TrkB АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ EA202090966A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762592657P 2017-11-30 2017-11-30
PCT/US2018/062863 WO2019108662A1 (en) 2017-11-30 2018-11-28 Anti-trkb monoclonal antibodies and methods of use

Publications (1)

Publication Number Publication Date
EA202090966A1 true EA202090966A1 (ru) 2020-08-26

Family

ID=64665125

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090966A EA202090966A1 (ru) 2017-11-30 2018-11-28 МОНОКЛОНАЛЬНЫЕ АНТИ-TrkB АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Country Status (16)

Country Link
US (2) US11066474B2 (ru)
EP (1) EP3717514A1 (ru)
JP (2) JP7438937B2 (ru)
KR (1) KR20200090779A (ru)
CN (1) CN111372949A (ru)
AU (1) AU2018375340A1 (ru)
BR (1) BR112020006976A2 (ru)
CA (1) CA3083452A1 (ru)
CL (1) CL2020000855A1 (ru)
CO (1) CO2020004075A2 (ru)
EA (1) EA202090966A1 (ru)
IL (1) IL273538A (ru)
MA (1) MA51207A (ru)
MX (1) MX2020003550A (ru)
SG (1) SG11202002665UA (ru)
WO (1) WO2019108662A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
WO2023125485A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkB ANTIBODY AND APPLICATION THEREOF

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6225282B1 (en) 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PA8678401A1 (es) 2005-06-06 2009-05-15 Wyeth Corp Anticuerpos monoclonales anti-trkb y sus usos
US20070248611A1 (en) * 2006-02-02 2007-10-25 Pfizer Inc Methods wanted for treating unwanted weight loss or eating disorders by administering a trkb agonist
WO2007088479A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
WO2008058127A2 (en) 2006-11-09 2008-05-15 Irm Llc Agonist trkb antibodies and uses thereof
BRPI0720473A2 (pt) 2006-12-20 2014-01-14 Rinat Neuroscience Corp Agonistas de trkb para tratamento de distúbios autoimunes
WO2009048605A1 (en) 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
JP5420568B2 (ja) 2008-01-17 2014-02-19 アイアールエム・リミテッド・ライアビリティ・カンパニー 改良された抗ＴｒｋＢ抗体
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2011103667A1 (en) 2010-02-26 2011-09-01 6452728 Canada Inc. Agonistic antibodies to trkb receptors and uses thereof
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
WO2015077672A1 (en) 2013-11-25 2015-05-28 The Regents Of The University Of California Santa Cruz Piericidin bacterial inhibitors
US10392438B2 (en) 2014-05-16 2019-08-27 Pfizer Inc. Bispecific antibodies
JP7023461B2 (ja) 2015-07-28 2022-02-22 オトノミ―，インク． 耳の疾病の処置のためのｔｒｋｂ又はｔｒｋｃアゴニスト組成物及び方法
US11078287B2 (en) 2015-11-17 2021-08-03 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
AU2017259966A1 (en) 2016-05-03 2018-11-22 The Scripps Research Institute TrkB agonist antibodies for treating neurodegenerative disorders
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
WO2018166495A1 (en) 2017-03-15 2018-09-20 Tsinghua University Novel anti-trkb antibodies

Also Published As

Publication number Publication date
IL273538A (en) 2020-05-31
CL2020000855A1 (es) 2020-07-31
WO2019108662A1 (en) 2019-06-06
US20190161551A1 (en) 2019-05-30
MA51207A (fr) 2020-10-07
CA3083452A1 (en) 2019-06-06
CO2020004075A2 (es) 2020-08-31
EP3717514A1 (en) 2020-10-07
JP2021507677A (ja) 2021-02-25
MX2020003550A (es) 2020-08-03
US20220411515A1 (en) 2022-12-29
CN111372949A (zh) 2020-07-03
SG11202002665UA (en) 2020-04-29
KR20200090779A (ko) 2020-07-29
JP7438937B2 (ja) 2024-02-27
AU2018375340A1 (en) 2020-05-07
US11066474B2 (en) 2021-07-20
BR112020006976A2 (pt) 2020-10-13
JP2024016204A (ja) 2024-02-06

Similar Documents

Publication Publication Date Title
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201790377A1 (ru) Антитела к глюкагону и их применения
MY169165A (en) Anti-pdgfr-beta antibodies and uses thereof
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201991207A1 (ru) Новые агонисты tnfr и их применение
EA201690212A8 (ru) Способы лечения или профилактики офтальмологических патологических состояний
EA201692109A1 (ru) Варианты антител к фактору d и их применение
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
PH12017500032A1 (en) Improved a� protofibril binding antibodies
EA201791005A1 (ru) Улучшенные антитела против il-6
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
EA202091482A1 (ru) Антитела
GT201800018A (es) Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
MX2021002321A (es) Nuevos metodos.
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
EA201691020A1 (ru) Способы лечения и предотвращения вызываемой аллогенными антителами хронической болезни "трансплантат против хозяина"
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
PH12020551007A1 (en) Anti-alpha-synuclein antibodies
EA202090966A1 (ru) МОНОКЛОНАЛЬНЫЕ АНТИ-TrkB АНТИТЕЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CO6592047A2 (es) Formulación tópica oftálmica de péptidos
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
MX2022014577A (es) Gel intestinal de levodopa y carbidopa y metodos de uso.
MX2018012250A (es) Agonistas de los receptores de acido retinoico alfa (rara) para el tratamiento de leucemia mieloide aguda (aml) y sindrome mielodisplasico (mds).
BR112018014964A2 (pt) células multipotentes e tecido microvascular melhorados e métodos de uso dos mesmos